Search PubMed⌕ Search

Biomedical subjects

M Abe

Publications and source records attributed to M Abe.

At least 1,315 records · Page 73Linked to original sources
PubMed1984

Clinical significance of radionuclide studies in the acute phase of myocardial infarction.

Tl201 MPS and MGCBS were performed on patients with myocardial infarction in the acute phase and the results were evaluated using a scoring system. The findings obtained in this study can be summarized as follows. There was a significant difference in RNEF between Killip class I and III. Significantly high correlation was noted between RWM score and RNEF. In cases of low RNEF (less than 35%) with poor RWM (less than 7), the incidence of complications, especially malignant PVC (47%, P less than 0.01) was markedly high. There was no obvious correlation between Tl201 MPS and complications. However, adding low RNEF (35% or less) to poor Tl scores (-22 or less) malignant PVC was noted with high frequency. Tl scores on admission were not related to the number of coronary arteries involved. For patients with good Tl score and low RNEF on admission (suspected of having severe ischemia), EF did not necessarily showed a tendency toward improvement. Patients with single-, tow- or three-vessel disease showed no difference in improvement of EF at discharge. There was no marked difference in Tl score on admission among three groups of single lesion of left anterior descending artery; patients with total occlusion without collateral circulation, patients with collateral circulation and patients with recanalization.

Adult↗
PubMed1984

Effects of L-carnitine on exercise tolerance in patients with stable angina pectoris.

The effects of L-carnitine (900 mg, p.o. daily) on exercise performance were studied in 12 patients with stable effort angina using a multistage treadmill exercise test. Exercise tests were performed at the end of the placebo period and after 4 and 12 weeks of carnitine therapy. While 12 patients experienced angina during treadmill tests in the placebo period, 2 patients were free of angina after treatment with carnitine. The mean exercise time was 11.4 +/- 0.7 min (mean +/- SE) in the placebo period. This increased significantly to 12.2 +/- 0.5 min (p less than 0.05) after 4 weeks and 12.8 +/- 0.5 min (p less than 0.01) after 12 weeks of treatment with carnitine. The time required for 1 mm ST depression to occur was 6.4 +/- 0.9 min in the placebo period. This increased significantly to 7.6 +/- 0.9 min (p less than 0.01) after 4 weeks and 8.8 +/- 1.0 min after 12 weeks of treatment with carnitine. There was significantly less ST segment depression during the same exercise load after 12 weeks of treatment as compared with that in the placebo period (p less than 0.05). The heart rate and the pressure rate product at the same work load showed no significant difference among the 3 testing periods. The results of this study suggest that L-carnitine may improve exercise tolerance in patients with effort angina.

Adult↗
PubMed1984

Separation of trace amounts of Ca2+ and Sr2+ from K+ and Rb+ with a hydrous manganese dioxide ion exchanger.

Extremely large separation factors (greater than 10(2)) were found for Na-Mg, K-Ca and Rb-Sr metal ion pairs on a cryptomelane-type hydrous manganese dioxide (CRYMO) ion exchanger. Ca2+ and Sr2+ ions were quantitatively separated from a thousand times of K+ and Rb+ ions on mole basis, respectively, by using the CRYMO column. The hopeful utilities of the CRYMO are suggested for the radiochemical ion-exchange separation of radiomagnesium and radiostrontium from K and Rb salt targets.

Calcium↗
PubMed1984

[Clinical evaluation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in hepatocellular carcinoma].

1-Hexylcarbamoyl-5-fluorouracil (HCFU) was administered orally to 63 patients with hepatocellular carcinoma (HCC) at a daily dose of 200 to 600 mg. Twenty three of those patients who received HCFU over 4 weeks without any other therapies were studied for its antitumor effect. Eighteen patients were evaluated for tumor size. The results showed a response rate of 16.7% (3/18) based on the criteria of Koyama et al. Patients with minute hepatoma had an especially good response; the response rate being 40% (2/5), or 60% (3/5) including minor response. Tests showed no aggravation of liver function. HCFU was considered to be useful in the treatment of HCC. However, unexpected adverse neurological effects were encountered in 6 patients. They began with slurred speech, bradypragia and gait disturbance, and finally progressed to unconsciousness in 4 out of 6 patients, in which the clinical picture resembled hepatic encephalopathy. Though reversible, these symptoms necessitate immediate withdrawal of HCFU therapy.

Administration, Oral↗
PubMed1984

[High dose ACNU and radiation therapy with autologous bone marrow rescue for a patient with cerebellar medulloblastoma: case report].

High dose ACNU and radiation therapy with autologous bone marrow rescue was performed in a 3-year-old boy suffering from cerebellar medulloblastoma, whose main mass had been removed at operation when widespread subarachnoid tumor dissemination was already present. The myelosuppression, which is a major side effect of high dose chemotherapy, was successfully prevented by the autologous bone marrow grafting and the serial CT scans showed complete disappearance of the tumor. However, the patient died on the 53rd day after the administration of ACNU of respiratory complication which was most likely due to pulmonary fibrosis. Although the autologous bone marrow rescue therapy is a technical advance to cope with myelosuppression secondary to chemotherapy, side effects of the other organs, particularly of the respiratory system, remain to be solved. The optimal treatment schedule should be established as soon as possible.

Antineoplastic Agents↗
PubMed1984

Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells.

We have monitored the effects of sodium butyrate on expression of a human breast tumor-associated antigen defined by a murine monoclonal antibody designated DF3. This cell surface antigen has a molecular weight of approximately 300,000 and is related to a higher-molecular-weight antigen detectable in human milk. The results demonstrate that butyrate increases the membrane expression of the DF3 tumor-associated antigen. Further, butyrate treatment specifically enhances production of the DF3-related milk antigen. These effects occur at butyrate concentrations lower than that required for maximal expression of carcinoembryonic antigen and occur in the absence of changes in the expression of nonspecific cross-reacting antigen. The results suggest that butyrate induces a more differentiated MCF-7 phenotype and that this model may be useful in studying maturation of human breast cancer cells.

Antibodies, Monoclonal↗